MetaVia Inc. (MTVA) shares rose following the presentation of new clinical data at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. The company presented three late-breaking abstracts during the event held from June 5-8.
The presentations highlighted DA-1726, a dual GLP-1/glucagon agonist currently in development for obesity. MetaVia also detailed vanoglipel, a GPR119 agonist targeting type 2 diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
The stock has gained over 60% since the abstracts were first accepted in mid-May. The ADA event provided significant market visibility for the company’s core pipeline assets.